Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

US7915252B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Sherman T. Waddell · Westfield, US
• James M. Balkovec · North Plainfield, US
• Gina M. Santorelli · Long Branch, US
• Aaron H. Leeman · Cranford, US
• Milana Maletic · Summit, US
• Xin Gu · Scotch Plains, US

Key dates

• Filing date: Aug 3, 2005
• Grant date: Mar 29, 2011
• Expiry date: Jul 13, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Sulfonyl derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM.